Stat3: Linking inflammation to epithelial cancer - more than a gut feeling?

Cell Division

Volumn 5, Issue , 2010, Pages

  Jarnicki, Andrew ^a   Putoczki, Tracy ^a   Ernst, Matthias ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MUS;

EID: 77954156529     PISSN: None     EISSN: 17471028     Source Type: Journal    
DOI: 10.1186/1747-1028-5-14     Document Type: Review

References (167)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
2. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78. 10.1038/nrc1256, 14708027.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998. 10.1038/ni1102-991, 12407406.
4. zur Hausen H. Papovaviruses and human tumors. Haematol Blood Transfus 1983, 28:289-292.
5. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527. 10.1056/NEJMoa021641, 12571259.
6. Niedobitek G, Meru N, Delecluse HJ. Epstein-Barr virus infection and human malignancies. Int J Exp Pathol 2001, 82:149-170. 10.1111/j.1365-2613.2001.iep190.x, 11488990.
7. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002, 101:415-422. 10.1002/ijc.10632, 12216068.
8. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535. 10.1136/gut.48.4.526, 1728259, 11247898.
9. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol 2008, 14:378-389. 10.3748/wjg.14.378, 2679126, 18200660.
10. Langman M, Boyle P. Chemoprevention of colorectal cancer. Gut 1998, 43:578-585. 1727277, 9824590.
11. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749-759. 10.1038/nri1703, 16175180.
12. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444. 10.1038/nature07205, 18650914.
13. Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, et al. Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. Nat Genet 1995, 10:143-150. 10.1038/ng0695-143, 7663509.
14. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, et al. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997, 150:91-97. 1858528, 9006326.
15. Shah SA, Simpson SJ, Brown LF, Comiskey M, de Jong YP, et al. Development of colonic adenocarcinomas in a mouse model of ulcerative colitis. Inflamm Bowel Dis 1998, 4:196-202.
16. Lacy-Hulbert A, Smith AM, Tissire H, Barry M, Crowley D, et al. Ulcerative colitis and autoimmunity induced by loss of myeloid alphav integrins. Proc Natl Acad Sci USA 2007, 104:15823-15828. 10.1073/pnas.0707421104, 1994135, 17895374.
17. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002, 109:1139-1142. 150969, 11994401.
18. Levy DE, Lee CK. What does Stat3 do?. J Clin Invest 2002, 109:1143-1148. 150972, 11994402.
19. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111. 10.1038/35074122, 11323675.
20. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007, 117:3846-3856. 10.1172/JCI31871, 2096430, 18060032.
21. Quesnelle KM, Boehm AL, Grandis JR. STAT-mediated EGFR signaling in cancer. J Cell Biochem 2007, 102:311-319. 10.1002/jcb.21475, 17661350.
22. Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998, 391:285-288. 10.1038/34657, 9440692.
23. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488. 10.1038/sj.onc.1203527, 10851046.
24. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005, 11:623-629. 10.1038/nm1249, 15895073.
25. Schlessinger K, Levy DE. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 2005, 65:5828-5834. 10.1158/0008-5472.CAN-05-0317, 2100417, 15994959.
26. Garcia R, Bowman TL, Niu G, Yu H, Minton S, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20:2499-2513. 10.1038/sj.onc.1204349, 11420660.
27. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci 2009, 1171:59-76. 10.1111/j.1749-6632.2009.04911.x, 19723038.
28. Ernst M, Oates A, Dunn AR. Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways. J Biol Chem 1996, 271:30136-30143. 10.1074/jbc.271.47.30136, 8939963.
29. Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. Embo J 1995, 14:1421-1429. 398228, 7537214.
30. Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002, 8:1089-1097. 10.1038/nm763, 12219085.
31. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 2005, 11:845-852. 10.1038/nm1282, 16041381.
32. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008, 118:1727-1738. 2323192, 18431520.
33. Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, et al. Stat3 is a negative regulator of intestinal tumor progression in ApcMin mice. Gastroenterology 2010, 138:1003-1011. 10.1053/j.gastro.2009.11.049, 19962983.
34. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765. 10.1146/annurev.immunol.19.1.683, 11244051.
35. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999, 10:39-49. 10.1016/S1074-7613(00)80005-9, 10023769.
36. Alonzi T, Newton IP, Bryce PJ, Di Carlo E, Lattanzio G, et al. Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. Cytokine 2004, 26:45-56. 10.1016/j.cyto.2003.12.002, 15050604.
37. Wolk K, Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006, 17:367-380. 10.1016/j.cytogfr.2006.09.001, 17030002.
38. Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 2004, 4:679-691. 10.1016/j.intimp.2004.01.008, 15120652.
39. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178:2623-2629.
40. El Kasmi KC, Smith AM, Williams L, Neale G, Panopoulos AD, et al. Cutting edge: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway. J Immunol 2007, 179:7215-7219.
41. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003, 4:540-545. 10.1038/ni931, 12754505.
42. Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, et al. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 2003, 4:546-550. 10.1038/ni932, 12754506.
43. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003, 4:551-556. 10.1038/ni938, 12754507.
44. Morgan KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 2008, 59:213-222. 10.1146/annurev.med.59.061506.154159, 17919086.
45. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009, 457:200-204. 10.1038/nature07475, 2695248, 19020503.
46. Greenhalgh CJ, Hilton DJ. Negative regulation of cytokine signaling. J Leukoc Biol 2001, 70:348-356.
47. He B, You L, Uematsu K, Zang K, Xu Z, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 2003, 100:14133-14138. 10.1073/pnas.2232790100, 283558, 14617776.
48. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci USA 2009, 106:9435-9440. 2687998, 19478061.
49. Zhang X, Guo A, Yu J, Possemato A, Chen Y, et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci USA 2007, 104:4060-4064. 10.1073/pnas.0611665104, 1802729, 17360477.
50. Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 2001, 409:349-354. 10.1038/35053086, 11201744.
51. Kim H, Hawley TS, Hawley RG, Baumann H. Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells. Mol Cell Biol 1998, 18:1525-1533. 108867, 9488469.
52. Chung CD, Liao J, Liu B, Rao X, Jay P, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997, 278:1803-1805. 10.1126/science.278.5344.1803, 9388184.
53. Maximo V, Lima J, Soares P, Silva A, Bento I, et al. GRIM-19 in Health and Disease. Adv Anat Pathol 2008, 15:46-53. 10.1097/PAP.0b013e31815e5258, 18156812.
54. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
55. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al. Stat3 as an oncogene. Cell 1999, 98:295-303. 10.1016/S0092-8674(00)81959-5, 10458605.
56. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, et al. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002, 21:8404-8413. 10.1038/sj.onc.1206047, 12466961.
57. Stephanou A, Brar BK, Knight RA, Latchman DS. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 2000, 7:329-330. 10.1038/sj.cdd.4400656, 10866494.
58. Zushi S, Shinomura Y, Kiyohara T, Miyazaki Y, Kondo S, et al. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer 1998, 78:326-330. 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4, 9766567.
59. Sikora A, Grzesiuk E. Heat shock response in gastrointestinal tract. J Physiol Pharmacol 2007, 58(Suppl 3):43-62.
60. Macadam RC, Sarela AI, Farmery SM, Robinson PA, Markham AF, et al. Death from early colorectal cancer is predicted by the presence of transcripts of the REG gene family. Br J Cancer 2000, 83:188-195. 10.1054/bjoc.2000.1227, 2363494, 10901369.
61. Velden JJ, van Marion AM, Kremer B, Straetmans JM, Henquet CJ, et al. Erythema nodosum as an early sign of Crohn's disease. Int J Dermatol 2007, 46(Suppl 3):27-29. 10.1111/j.1365-4632.2007.03507.x, 17973885.
62. Ivanov VN, Bhoumik A, Krasilnikov M, Raz R, Owen-Schaub LB, et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 2001, 7:517-528. 10.1016/S1097-2765(01)00199-X, 11463377.
63. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000, 97:13103-13107. 10.1073/pnas.240390697, 27185, 11069302.
64. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70. 10.1038/nrc2293, 18075512.
65. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002, 62:3351-3355.
66. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 2001, 98:7319-7324. 10.1073/pnas.131568898, 34666, 11404481.
67. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, et al. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 2001, 37:581-586.
68. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102. 10.1016/j.ccr.2009.01.002, 19185844.
69. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004, 23:4921-4929. 10.1038/sj.onc.1207606, 15077160.
70. Chen CL, Cen L, Kohout J, Hutzen B, Chan C, et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer 2008, 7:78. 10.1186/1476-4598-7-78, 2577686, 18939995.
71. Wei D, Le X, Zheng L, Wang L, Frey JA, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003, 22:319-329. 10.1038/sj.onc.1206122, 12545153.
72. Niu G, Wright KL, Huang M, Song L, Haura E, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008. 10.1038/sj.onc.1205260, 11960372.
73. Kim HL, Cassone M, Otvos L, Vogiatzi P. HIF-1alpha and STAT3 client proteins interacting with the cancer chaperone Hsp90: therapeutic considerations. Cancer Biol Ther 2008, 7:10-14. 10.1158/1535-7163.MCT-07-0192, 18347418.
74. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008, 118:3367-3377. 10.1172/JCI35213, 2528912, 18776941.
75. Choi JH, Ahn MJ, Park CK, Han HX, Kwon SJ, et al. Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray. Apmis 2006, 114:619-625. 10.1111/j.1600-0463.2006.apm_401.x, 16948814.
76. Gong W, Wang L, Yao JC, Ajani JA, Wei D, et al. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 2005, 11:1386-1393. 10.1158/1078-0432.CCR-04-0487, 15746037.
77. Laird AD, Li G, Moss KG, Blake RA, Broome MA, et al. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Mol Cancer Ther 2003, 2:461-469.
78. Valdembri D, Serini G, Vacca A, Ribatti D, Bussolino F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. Faseb J 2002, 16:225-227.
79. Jackson CB, Giraud AS. STAT3 as a prognostic marker in human gastric cancer. J Gastroenterol Hepatol 2009, 24:505-507. 10.1111/j.1440-1746.2009.05822.x, 19368630.
80. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009, 27:2383-2392. 10.1002/stem.185, 19658181.
81. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 2006, 66:3188-3196. 10.1158/0008-5472.CAN-05-2674, 16540670.
82. Chan KS, Sano S, Kataoka K, Abel E, Carbajal S, et al. Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene 2008, 27:1087-1094. 10.1038/sj.onc.1210726, 17700521.
83. Ward JM, Diwan BA, Ohshima M, Hu H, Schuller HM, et al. Tumor-initiating and promoting activities of di(2-ethylhexyl) phthalate in vivo and in vitro. Environ Health Perspect 1986, 65:279-291. 10.2307/3430195, 1474721, 3709454.
84. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113. 10.1016/j.ccr.2009.01.001, 2667107, 19185845.
85. Rigby RJ, Simmons JG, Greenhalgh CJ, Alexander WS, Lund PK. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 2007, 26:4833-4841. 10.1038/sj.onc.1210286, 17297444.
86. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004, 114:720-728. 514583, 15343391.
87. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005, 4:217-220.
88. Schneider DT, Lemburg P, Sprock I, Heying R, Gobel U, et al. Introduction of the oncological pediatric risk of mortality score (O-PRISM) for ICU support following stem cell transplantation in children. Bone Marrow Transplant 2000, 25:1079-1086. 10.1038/sj.bmt.1702403, 10828869.
89. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000, 6:583-588. 10.1038/75068, 10802717.
90. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501. 10.1016/j.immuni.2004.07.020, 15485627.
91. Maione D, Di Carlo E, Li W, Musiani P, Modesti A, et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. Embo J 1998, 17:5588-5597. 10.1093/emboj/17.19.5588, 1170887, 9755159.
92. Wang RJ, Peng RY, Fu KF, Gao YB, Han RG, et al. Effect of recombinant human interleukin-11 on expressions of interleukin-11 receptor alpha-chain and glycoprotein 130 in intestinal epithelium cell line-6 after neutron irradiation. World J Gastroenterol 2006, 12:3055-3059.
93. Ernst M, Phesse T, Jenkins B, Buchert M, McKenzie B, et al. Linking inflammation to cancer-A novel role for Stat3. Cytokine 2010, 48:44.
94. Li Y, Du H, Qin Y, Roberts J, Cummings OW, et al. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res 2007, 67:8494-8503. 10.1158/0008-5472.CAN-07-0647, 17875688.
95. Judd LM, Bredin K, Kalantzis A, Jenkins BJ, Ernst M, et al. STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology 2006, 131:1073-1085. 10.1053/j.gastro.2006.07.018, 17030178.
96. Putoczki T, Thiem S, Jarnicki AG, Jenkins B, McKenzie B, et al. IL-11 mediated Stat3 activation in inflammation and cancer. Cytokine 2010, 48:7.
97. Gaspar C, Franken P, Molenaar L, Breukel C, Valk M, et al. A targeted constitutive mutation in the APC tumor suppressor gene underlies mammary but not intestinal tumorigenesis. PLoS Genet 2009, 5:e1000547. 10.1371/journal.pgen.1000547, 2697381, 19578404.
98. Buchert M, Athineos D, Abud HE, Burke ZD, Faux MC, et al. Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet 1000, 6:e1000816.
99. Consortium TWTCC Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678. 10.1038/nature05911, 2719288, 17554300, Consortium TWTCC.
100. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008, 14:275-281. 10.1038/nm1710, 18264110.
101. Zenewicz LA, Flavell RA. IL-22 and inflammation: leukin' through a glass onion. Eur J Immunol 2008, 38:3265-3268. 10.1002/eji.200838655, 19016525.
102. Mejias-Luque R, Linden SK, Garrido M, Tye H, Najdovska M, et al. Inflammation modulates the expression of the intestinal mucins MUC2 and MUC4 in gastric tumors. Oncogene 2010,
103. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009, 206:1465-1472. 10.1084/jem.20082683, 2715097, 19564350.
104. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008, 118:534-544. 2157567, 18172556.
105. Ziesche E, Bachmann M, Kleinert H, Pfeilschifter J, Muhl H. The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 2007, 282:16006-16015. 10.1074/jbc.M611040200, 17438334.
106. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005, 65:939-947.
107. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol 1999, 11:490-496. 10.1097/00001622-199911000-00010, 10550013.
108. Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, et al. aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci USA 2009, 106:16369-16374. 10.1073/pnas.0907044106, 2752573, 19805306.
109. Rabinovich A, Medina L, Piura B, Segal S, Huleihel M. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res 2007, 27:267-272.
110. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007, 21:1714-1719. 10.1101/gad.1549407, 1920165, 17639077.
111. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, et al. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-1716. 10.1126/science.1171721, 2840701, 19556508.
112. Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, et al. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:793-797. 10.1126/science.1164551, 2758306, 19131594.
113. Nakayama T, Yoshizaki A, Izumida S, Suehiro T, Miura S, et al. Expression of interleukin-11 (IL-11) and IL-11 receptor alpha in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells. Int J Oncol 2007, 30:825-833.
114. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127. 10.1126/science.1140488, 17615359.
115. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124. 10.1126/science.1140485, 17615358.
116. Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol 2007, Chapter 14(Unit 14):12.
117. Eckmann L, Nebelsiek T, Fingerle AA, Dann SM, Mages J, et al. Opposing functions of IKKbeta during acute and chronic intestinal inflammation. Proc Natl Acad Sci USA 2008, 105:15058-15063. 10.1073/pnas.0808216105, 2567492, 18815378.
118. Takahashi H, Ogata H, Nishigaki R, Broide D, Karin M. Tobacco Smoke Promotes Lung Tumorigenesis by Triggering IKKβ- and JNK1-Dependent Inflammation. Cancer Cell 2010, 17:89-97. 10.1016/j.ccr.2009.12.008, 20129250.
119. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296. 10.1016/j.cell.2004.07.013, 15294155.
120. Esfandi F, Mohammadzadeh Ghobadloo S, Basati G. Interleukin-6 level in patients with colorectal cancer. Cancer Lett 2006, 244:76-78. 10.1016/j.canlet.2005.12.003, 16442710.
121. Okada S, Okusaka T, Ishii H, Kyogoku A, Yoshimori M, et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol 1998, 28:12-15. 10.1093/jjco/28.1.12, 9491135.
122. Hoheisel G, Izbicki G, Roth M, Chan CH, Reichenberger F, et al. Proinflammatory cytokine levels in patients with lung cancer and carcinomatous pleurisy. Respiration 1998, 65:183-186. 10.1159/000029256, 9670298.
123. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001, 159:2159-2165. 1850613, 11733366.
124. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008, 14:156-165. 10.1016/j.ccr.2008.06.016, 2707922, 18691550.
125. Baltgalvis KA, Berger FG, Pena MM, Davis JM, Muga SJ, et al. Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol 2008, 294:R393-401.
126. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54. 10.1038/nm976, 14702634.
127. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2:1096-1103. 10.1038/nm1096-1096, 8837607.
128. Gur-Wahnon D, Borovsky Z, Liebergall M, Rachmilewitz J. The induction of APC with a distinct tolerogenic phenotype via contact-dependent STAT3 activation. PLoS One 2009, 4:e6846. 10.1371/journal.pone.0006846, 2731174, 19718269.
129. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114-123. 10.1016/j.ccr.2008.12.018, 2673504, 19185846.
130. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005, 11:1314-1321. 10.1038/nm1325, 16288283.
131. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005, 175:6177-6189.
132. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, et al. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465. 10.1038/nature04808, 16688182.
133. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009, 206:1457-1464. 10.1084/jem.20090207, 2715087, 19564351.
134. Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 2006, 103:8137-8142. 10.1073/pnas.0600666103, 1459629, 16698929.
135. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132. 10.1038/ni1254, 16200070.
136. Nishihara M, Ogura H, Ueda N, Tsuruoka M, Kitabayashi C, et al. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. Int Immunol 2007, 19:695-702. 10.1093/intimm/dxm045, 17493959.
137. Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 2009, 326:986-991. 10.1126/science.1172702, 19797626.
138. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008, 453:1051-1057. 10.1038/nature07036, 18563156.
139. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009, 15:1016-1022. 10.1038/nm.2015, 19701202.
140. Caruso R, Pallone F, Monteleone G. Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol 2007, 13:5547-5551.
141. Howlett M, Judd LM, Jenkins B, La Gruta NL, Grail D, et al. Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130. Gastroenterology 2005, 129:1005-1018. 10.1053/j.gastro.2005.06.068, 16143138.
142. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006, 7:937-945. 10.1038/ni1376, 16906166.
143. Erez N, Truitt M, Olson P, Hanahan D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell 2010, 17:135-147. 10.1016/j.ccr.2009.12.041, 20138012.
144. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706. 10.1016/j.cell.2009.10.014, 19878981.
145. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15:283-293. 10.1016/j.ccr.2009.02.015, 2777654, 19345327.
146. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947. 10.1038/onc.2009.180, 19581928.
147. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, et al. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15:416-428. 10.1016/j.ccr.2009.03.016, 19411070.
148. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 2007, 21:1396-1408. 10.1101/gad.1553707, 1877751, 17510282.
149. Hegde S, Ni S, He S, Yoon D, Feng GS, et al. Stat3 promotes the development of erythroleukemia by inducing Pu.1 expression and inhibiting erythroid differentiation. Oncogene 2009, 28:3349-3359. 10.1038/onc.2009.202, 19581930.
150. Jiang H, Patel PH, Kohlmaier A, Grenley MO, McEwen DG, et al. Cytokine/Jak/Stat signaling mediates regeneration and homeostasis in the Drosophila midgut. Cell 2009, 137:1343-1355. 10.1016/j.cell.2009.05.014, 19563763.
151. Hall J, Guo G, Wray J, Eyres I, Nichols J, et al. Oct4 and LIF/Stat3 additively induce Kruppel factors to sustain embryonic stem cell self-renewal. Cell Stem Cell 2009, 5:597-609. 10.1016/j.stem.2009.11.003, 19951688.
152. McConnell BB, Klapproth JM, Sasaki M, Nandan MO, Yang VW. Kruppel-like factor 5 mediates transmissible murine colonic hyperplasia caused by Citrobacter rodentium infection. Gastroenterology 2008, 134:1007-1016. 10.1053/j.gastro.2008.01.013, 2336106, 18395082.
153. Shields BJ, Hauser C, Bukczynska PE, Court NW, Tiganis T. DNA replication stalling attenuates tyrosine kinase signaling to suppress S phase progression. Cancer Cell 2008, 14:166-179. 10.1016/j.ccr.2008.06.003, 18691551.
154. Dikovskaya D, Schiffmann D, Newton IP, Oakley A, Kroboth K, et al. Loss of APC induces polyploidy as a result of a combination of defects in mitosis and apoptosis. J Cell Biol 2007, 176:183-195. 10.1083/jcb.200610099, 2063938, 17227893.
155. Verma NK, Dourlat J, Davies AM, Long A, Liu WQ, et al. STAT3-stathmin interactions control microtubule dynamics in migrating T-cells. J Biol Chem 2009, 284:12349-12362. 10.1074/jbc.M807761200, 2673303, 19251695.
156. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448:1058-1062. 10.1038/nature06096, 17676033.
157. Shen Y, Schlessinger K, Zhu X, Meffre E, Quimby F, et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 2004, 24:407-419. 10.1128/MCB.24.1.407-419.2004, 303338, 14673173.
158. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16:487-497. 10.1016/j.ccr.2009.10.015, 19962667.
159. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005, 11:595-596. 10.1038/nm0605-595, 15937466.
160. Groner B, Lucks P, Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 2008, 19:341-350. 10.1016/j.semcdb.2008.06.005, 18621135.
161. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009, 27:925-932. 10.1038/nbt.1564, 2846721, 19749770.
162. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837. 10.1016/j.cell.2009.02.024, 19269363.
163. Park EJ, Lee JH, Yu GY, He G, Ali SR, et al. Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression. Cell 2009, 140:197-208.
164. Johnstone CN, White SJ, Tebbutt NC, Clay FJ, Ernst M, et al. Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression. Journal of Biological Chemistry 2002, 277:34351-34359.
165. Ernst M, Jenkins B. Acquiring signalling specificity from the cytokine receptor gp130. Trends in Genetics 2004, 20:23-32. 10.1016/j.tig.2003.11.003, 14698616.
166. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer 2009, 9:798-809. 10.1038/nrc2734, 19851315.
167. Erez N, Truitt M, Olson P, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kB-dependent manner. Cancer Cell 2010, 17:135-147. 10.1016/j.ccr.2009.12.041, 20138012.